Biocompatibility for FDA: Clear, Defensible, Reviewer-Friendly
Turn your device’s materials, contact type, and contact duration into a clear biological evaluation plan and report that follows FDA’s risk-based framework — without unnecessary testing or review delays.
When Your FDA Biocompatibility Strategy Needs Support
- You must define the correct contact type and duration for a new device.
- You’re unsure which biological effects (endpoints) apply.
- You want to avoid unnecessary biocompatibility testing.
- You need to repackage old data into FDA’s expected format.
- You’re preparing a 510(k), De Novo, or PMA and want to reduce reviewer questions.
- You need a BEP/BER that aligns with FDA’s 2023 guidance and ISO 10993-1.
What FDA Reviewers Expect Today
FDA’s 2023 guidance makes ISO 10993-1 the backbone of biocompatibility for 510(k), De Novo, and PMA submissions. The agency now expects a risk-based evaluation, not automatic testing.
FDA also defines which endpoints apply based on contact type and contact duration. Your plan and report must follow this structure to avoid reviewer questions.
When chemistry feeds toxicology, FDA’s TEEM tool uses ISO 10993-17 logic for exposure and safety margins. Clean 10993-1 reasoning prevents back-and-forth.
For 510(k), the eSTAR template requires biocompatibility content in specific fields. A structured narrative makes your submission easier to review.
The New Structure of Biological Evaluation
With FDA’s 2023 guidance and the upcoming ISO 10993-1 update, the logic behind biological evaluation is changing. To make these updates easier to navigate, we prepared a clear before/after guide to ISO 10993-1:2025.
Download for free and understand what changed in the new ISO 10993-1 and how the updated framework reshapes FDA’s risk-based biocompatibility expectations.
How We Build a Clean, FDA-Ready Biocompatibility Assessment
We turn your device’s description, materials, and available evidence into a structured biological evaluation that follows FDA’s current guidance and ISO 10993-1 logic — clear, defensible, and reviewer-friendly.
Categorize the Device: We document body-contact type and contact duration, and justify why each classification applies. This determines which biological effects must be addressed.
Map Endpoints and Rationale: Using FDA’s tables, we identify the biological effects you must evaluate and show how each one will be addressed: via existing evidence, chemistry, literature, or testing only when necessary.
Evidence Before Testing: We review materials information, chemistry/E&L data, and literature to justify biocompatibility without unnecessary tests — fully aligned with FDA’s risk-based stance.
Write the BEP & BER: You receive a clear Biological Evaluation Plan and Report with traceability, conclusions, and reviewer-style Q&A. If your team uses eSTAR, we map content to the relevant fields to reduce reviewer navigation time.
Your Reviewer-Ready Biocompatibility Package
Get a complete set of documents that organize your device’s biocompatibility in a way FDA reviewers can follow quickly — structured, traceable, and aligned with the agency’s current expectations.
The New Structure of Biological Evaluation
With FDA’s 2023 guidance and the upcoming ISO 10993-1 update, the logic behind biological evaluation is changing. To make these updates easier to navigate, we prepared a clear before/after guide to ISO 10993-1:2025.
Download for free and understand what changed in the new ISO 10993-1 and how the updated framework reshapes FDA’s risk-based biocompatibility expectations.
Why Teams Trust Sobel’s FDA Biocompatibility Work
Sobel supports global manufacturers with FDA submissions grounded in ISO 10993-1 risk logic, evidence clarity, and reviewer-friendly explanations.
Our approach turns complex materials and chemistry information into a coherent narrative that reduces questions and accelerates review.
Contact type/duration logic aligned with FDA’s 2023 guidance
Clear endpoint selection tied to FDA’s published tables
Traceable reasoning from evidence → decision → conclusion
Fewer reviewer questions through structured documentation
Risk-based evaluation that avoids unnecessary testing
Outputs formatted to match eSTAR reviewer workflows
Ready to Build an FDA-Compliant Biocompatibility Strategy?
Our team helps you translate your device’s design, materials, and existing evidence into a clear biocompatibility narrative aligned with FDA expectations — without creating unnecessary testing or back-and-forth.
Contact Us
We would love to speak with you.
Feel free to reach out using the below details.
